New Novartis and ISAB poster at ISAM
A joint poster from Novartis and Inhalation Sciences AB (ISAB), at the International Society for Aerosols in Medicine (ISAM) conference, June 4-7, shows the results of a collaboration that used ISAB’s aerosol generator PreciseInhale to test the formulation technologies: PulmoSol and PulmoSphere.
Novartis is one of the world’s most innovative pharma companies, developing new treatments and therapies that the company describe as ‘reimagining medicine’. Between September and October 2016 Novartis chose ISAB’s pioneering PreciseInhale to test two high-potential formulation technologies. The challenge was to discover if PreciseInhale could aerosolize both formulations to respirable particle size—and deliver yields sufficient for use in pre-clinical studies
Mattias Nowenwik, analytical chemist and ISAB’s product development formulation specialist, co-authored the paper: “Both formulations are strategically important for Novartis, and challenging in their own different ways. PulmoSol particles are typically used to formulate macromolecules for pulmonary delivery. PulmoSphere particles are phospholipid-based, small porous particles.”
The full results and methodology are revealed in a poster presented at the ISAM conference, June 4-7, Santa Fe. The poster, titled Aerosolizing PulmoSol™ and PulmoSphere™ with the PreciseInhale® system will be on display, together with a complete PreciseInhale labtech system.
Fredrik Sjövall, ISAB CEO: “Visitors can get hands-on and see for themselves how PreciseInhale can aerosolize even challenging substances, helping eliminate weak candidates and saving significant sums in the early stage of drug development. Novartis is a particularly pioneering company who value innovation as much as we do. We are very proud to have worked with them.”
To read more about other ISAB customers go here.
To read more about PreciseInhale go here.